A Comparative Study of Effects of Berry and Grain Products on Postprandial Glycemic Response in Healthy Subjects
|ClinicalTrials.gov Identifier: NCT01575509|
Recruitment Status : Completed
First Posted : April 11, 2012
Last Update Posted : June 15, 2012
|Condition or disease||Intervention/treatment|
|Healthy||Other: Berry product Other: Bread product Other: Glucose control solution Other: Glucose-fructose control solution|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||14 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Clinical, Randomized, Comparative Study of Effects of Berry and Grain Products on Postprandial Glycemic Response in Healthy Subjects|
|Study Start Date :||March 2012|
|Primary Completion Date :||June 2012|
|Study Completion Date :||June 2012|
Other: Berry product
- The 2 hours glycemic responses to test products and control solutions [ Time Frame: 2 hours ]Capillary blood samples are taken before and at 15, 30, 45, 60, 90 and 120 min after starting to eat the test products or control solutions for measurements of plasma glucose concentrations.
- The 2 hours insulinemic responses to dried lingonberry product and corresponding control solution [ Time Frame: 2 hours ]Capillary blood samples are collected before and at 15, 30, 45, 60, 90 and 120 min after eating the lingonberry test product and glucose-fructose control solution. The serum insulin concentrations are analysed.
- The incremental area under glucose curve (IAUC) of bread test products [ Time Frame: 2 hours ]IAUC (mmol/l x min) is determined using the trapezoidal method for each subject and bread test product and corresponding glucose control solution.
- Glycemic index (GI) of bread test productsThe GI is calculated as a percentage of the glucose IAUC values of a bread product and a glucose control solution.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01575509
|Clinical Life Sciences Ltd|
|Kajaani, Finland, 87100|
|Principal Investigator:||Päivi Cheney, MD|